Treatment With Mycophenolate and Cyclophosphamide Leads to Clinically Meaningful Improvements in Patient‐Reported Outcomes in Scleroderma Lung Disease: Results of Scleroderma Lung Study II

Treatment With Mycophenolate and Cyclophosphamide Leads to Clinically Meaningful Improvements in Patient‐Reported Outcomes in Scleroderma Lung Disease: Results of Scleroderma Lung Study II

Objective Our objective was to determine if treatment with cyclophosphamide (CYC) and mycophenolate mofetil (MMF) improves patient‐reported outcomes (PROs) among patients with systemic sclerosis‐related interstitial lung disease (SSc‐ILD). Methods This study examined PROs in patients with SSc‐ILD (N...

Full description

Bibliographic Details
Main Authors: Elizabeth R. Volkmann, Donald P. Tashkin, Holly LeClair, Michael D. Roth, Grace Kim, Jonathan Goldin, Philip J. Clements, Daniel E. Furst, Dinesh Khanna
Format: Article
Language:English
Published: Wiley 2020-06-01
Series:ACR Open Rheumatology
Online Access:https://doi.org/10.1002/acr2.11125

Internet

https://doi.org/10.1002/acr2.11125

Similar Items